- Home
- STIM
STIM
Neuronetics Inc.
as 02-21-2025 4:00pm EST
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | MALVERN |
| Market Cap: | 192.0M | IPO Year: | 2018 |
| Target Price: | $4.67 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.52 - $5.07 | Next Earning Date: | 03-04-2025 |
| Revenue: | $72,711,000 | Revenue Growth: | 5.03% |
| Revenue Growth (this year): | 3.23% | Revenue Growth (next year): | 29.55% |
Stock Insider Trading Activity of Neuronetics Inc. (STIM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MACAN WILLIAM ANDREW | STIM | EVP, GC, CCO and CS | Feb 14 '25 | Sell | $4.11 | 18,965 | $77,946.15 | 369,682 | |
| MACAN WILLIAM ANDREW | STIM | EVP, GC, CCO and CS | Feb 12 '25 | Sell | $3.83 | 12,175 | $46,630.25 | 369,682 | |
| Furlong Stephen | STIM | EVP, CFO and Treasurer | Feb 12 '25 | Sell | $3.83 | 10,845 | $41,536.35 | 471,727 | |
| Furlong Stephen | STIM | EVP, CFO and Treasurer | Feb 10 '25 | Sell | $3.28 | 14,836 | $48,662.08 | 471,727 | |
| Sullivan Keith J | STIM | President and CEO | Feb 10 '25 | Sell | $3.28 | 40,992 | $134,453.76 | 1,283,362 |
Latest Neuronetics Inc. News
STIM Breaking Stock News: Dive into STIM Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call
Simply Wall St.
13 days ago
News Flash: Analysts Just Made A Stunning Upgrade To Their Neuronetics, Inc. (NASDAQ:STIM) Forecasts
GlobeNewswire
15 days ago
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
16 days ago
Neuronetics Prices Eight Million Share Offering at $2.25 Per Share
GlobeNewswire
16 days ago
Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock
GlobeNewswire
16 days ago
Neuronetics Announces Launch of Underwritten Public Offering of Common Stock
Insider Monkey
19 days ago
Why Neuronetics Inc (STIM) Is Skyrocketing So Far In 2025
GlobeNewswire
25 days ago
NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression
Compare STIM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STIM Neuronetics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.